Imtherapeutics

1 known investors

Imtherapeutics develops oral therapies for Type 1 diabetes patients with specific genetic markers. The company's AMT-002 candidate is designed to selectively block autoantigens that trigger autoimmunity in patients with the HLA-DQ8 genetic allele.

Biotech